Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.846,55 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
FR0000120578
Filter zurücksetzen
© Globe Newswire
27.11.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi investit 50 millions d’euros au Trait pour accélérer la production de médicaments innovants
Article
News Preview
Sanofi investit 50 millions d’euros au Trait pour accélérer la production de médicaments innovants...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Article
News Preview
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Article
News Preview
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
13.11.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares – October 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
07.11.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Article
News Preview
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi ancre son futur en France avec un nouveau siège emblématique à Paris La Défense
Article
News Preview
Sanofi ancre son futur en France avec un nouveau siège emblématique à Paris La Défense...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Sanofi successfully prices USD 3 billion of bond issue
Article
News Preview
Sanofi successfully prices USD 3 billion of bond issue  ...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Q3: continued sales and earnings progress
Article
News Preview
Q3: continued sales and earnings progress...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Article
News Preview
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Article
News Preview
Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Article
News Preview
  ...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Article
News Preview
...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Article
News Preview
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Article
News Preview
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Article
News Preview
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes
Article
News Preview
Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - September 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Article
News Preview
AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Article
News Preview
AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Article
News Preview
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Availability of the Q3 2025 Aide mémoire
Article
News Preview
 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Article
News Preview
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Article
News Preview
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Article
News Preview
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Article
News Preview
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - August 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Article
News Preview
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Article
News Preview
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes        ...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Article
News Preview
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Article
News Preview
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre
Article
News Preview
 Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Article
News Preview
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.08.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - July 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Article
News Preview
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Online availability of Sanofi’s half-year financial report for 2025
Article
News Preview
Online availability of Sanofi’s half-year financial report for 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Article
News Preview
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Article
News Preview
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Efluelda®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026
Article
News Preview
Efluelda®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Article
News Preview
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi completes acquisition of Blueprint Medicines
Article
News Preview
Sanofi completes acquisition of Blueprint Medicines...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi announces extension of Blueprint tender offer
Article
News Preview
Sanofi announces extension of Blueprint tender offer...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Article
News Preview
Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - June 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.07.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Communiqué de presse : Sanofi fait galoper Zeus, le cheval mécanique de la cérémonie d’ouverture des Jeux Olympiques, au Mont-Saint-Michel
Article
News Preview
                                 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
Article
News Preview
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Article
News Preview
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Article
News Preview
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Article
News Preview
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Article
News Preview
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - May 2025
Article
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Article
News Preview
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Article
News Preview
Sanofi Launches 2025 Global Employee Stock Purchase Plan...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Article
News Preview
ASCO: new Sarclisa data support subcutaneous administration with on-body injector...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Article
News Preview
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Article
News Preview
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Article
News Preview
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Article
News Preview
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Article
News Preview
Itepekimab met the primary endpoint in one of two COPD phase 3 studies...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.05.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi completes acquisition of DR-0201
Article
News Preview
Sanofi completes acquisition of DR-0201...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Article
News Preview
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.